Table 1.
Clinical Characteristics and Pathologic Features of KRAS-Mutant, KRAS-Wild-Type and Impractical KRAS in Colorectal Cancer Cases.
| Characteristic | KRAS Wild-Type (n = 35) |
KRAS Mutated (n = 50) |
Impractical KRAS (Not Tested) (n = 23) |
p-Value |
|---|---|---|---|---|
| Patient characteristics | ||||
| Age (year) a | 71 (63–76) | 69 (58–73) | 70 (66–76) | 0.281 b |
| Female sex | 14 (40.0%) | 16 (32.0%) | 9 (39.1%) | 0.709 c |
| Primary tumour characteristics | ||||
| T3 or T4 | 30 (85.7%) | 46 (92.0%) | 18 (78.3%) | 0.444 c |
| N1–N2 | ||||
| CRLM characteristics | 26 (74.3%) | 40 (80.0%) | 0 (0%) | <0.0001 c |
| Stage II or III | 6 (17.1%) | 17 (34.0%) | 18 (78.3%) | <0.0001 c |
| Synchronous CRLM | 29 (82.9%) | 33 (66.0%) | 0 (0%) | <0.0001 c |
| Tumour Burden Score a | 3.4 (2.1–4.9) | 4.0 (2.9–6.2) | 3.5 (2.7–5.2) | 0.048 b |
| Tumour number a | 2 (1.0–3.0) | 2 (1.0–3.3) | 1 (1.0–3.0) | 0.159 b |
| Size of largest tumour size (cm) a | 2 (1.5–3.6) | 2.8 (2.0–5.1) | 2.9 (2.2–4.2) | 0.040 b |
| Surgery procedure | ||||
| Anatomical | 12 (34.3%) | 28 (56.0%) | 9 (39.1%) | 0.112 c |
| Atypical | 23 (65.7%) | 22 (44.0%) | 14 (60.9%) | |
| R1 margin resection status | 9 (25.7%) | 19 (38.0%) | 4 (17.4%) | 0.166 c |
| Chemotherapy | ||||
| Preoperatively | 9 (25.7%) | 10 (20.0%) | 5 (21.7%) | 0.822 c |
| Postoperatively | 21 (60.0%) | 33 (66.0%) | 6 (26.1%) | 0.05 c |
| Cetuximab preoperatively | 0 (0%) | 3 (6.0%) | 0 (0%) | 0.165 c |
| Cetuximab postoperatively | 1 (2.8%) | 5 (10.0%) | 0 (0%) | 0.182 c |
CRLM, colorectal liver metastases. a Continuous variables are expressed as median (interquartile range). Categorical variables are expressed as absolute numbers and percentages. b Kruskal–Wallis test, c Chi-square test. Differences in variables were significant at a threshold of p < 0.05.